Clinical utilization patterns of alvimopan in a contemporary cohort of patients undergoing radical cystectomy
Objective: To evaluate the clinical utilization patterns and outcomes of alvimopan, a peripherally-acting µ-opioid receptor antagonist, after radical cystectomy (RC) and urinary diversion at a high-volume cancer center.
Patients and Methods: We retrospectively identified 130 consecutive patients who underwent RC and urinary diversion for bladder cancer at our institution from October 2013 to September 2014. Demographic, clinical, and postoperative outcomes were compared between patients who did and did not receive alvimopan using the Kruskal-Wallis test for medians and the chi-square test for proportions. Predictors of 30-day complications and prolonged length of stay (LOS) were analyzed using multivariate logistic regression analysis.
Results: Perioperative alvimopan was given to 81 patients (62.3%) during the study period although in 17 patients (13.1%) it was indicated but not given. The most common absolute or relative contraindication for alvimopan usage was prior consumption of opioids for more than 7 consecutive days (n=18; 13.8%). Patients who received alvimopan had a better performance status (p=0.06), less comorbidities (p=0.08), and were more likely to have minimally-invasive surgery (p=0.07) although these differences did not reach statistical significance. Alvimopan usage was independently associated with less postoperative 30-day complications (odds ratio [OR]: 0.35, 95% confidence interval [CI]: 0.15 – 0.82; p=0.015), less high-grade complications (OR: 0.12, 95% CI: 0.044 – 0.34; p<0.01), and less prolonged hospitalization >10 days (OR: 0.28, 95% CI: 0.11 – 0.72; p=0.008).
Conclusions: Despite its clinical benefits, alvimopan was under-utilized in RC patients, especially in those with worse baseline health. We recommend its incorporation into standardized protocols to optimize perioperative care.
1. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, et al. (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65: 778-792.
2. Ramirez JA, McIntosh AG, Strehlow R, Lawrence VA, Parekh DJ, et al. (2013) Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: a systematic review. Eur Urol 64: 588-597.
3. Chang SS, Baumgartner RG, Wells N, Cookson MS, Smith JA, Jr. (2002) Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol 167: 208-211.
4. Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith JA, Jr. (2002) Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 167: 2012-2016.
5. Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, et al. (2001) Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 345: 935-940.
6. Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, et al. (2014) Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol 66: 265-272.
7. Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, et al. (2014) Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol 191: 1721-1727.
8. Jansen JP, Lorch D, Langan J, Lasko B, Hermanns K, et al. (2011) A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 12: 185-193.
9. Webster L, Jansen JP, Peppin J, Lasko B, Irving G, et al. (2008) Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 137: 428-440.
10. Herzog TJ, Coleman RL, Guerrieri JP, Jr., Gabriel K, Du W, et al. (2006) A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol 195: 445-453.
11. Ludwig K, Enker WE, Delaney CP, Wolff BG, Du W, et al. (2008) Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg 143: 1098-1105.
12. Viscusi ER, Goldstein S, Witkowski T, Andonakakis A, Jan R, et al. (2006) Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 20: 64-70.
13. Cerantola Y, Valerio M, Persson B, Jichlinski P, Ljungqvist O, et al. (2013) Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS((R))) society recommendations. Clin Nutr 32: 879-887.
14. Pruthi RS, Nielsen M, Smith A, Nix J, Schultz H, et al. (2010) Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg 210: 93-99.